IL6 and myelodysplastic syndrome: IL-6 is a co-stimulator of vitro bone marrow mesenchymal stem cells.[3,8] We assume that anti-IL-6 monoclonal antibody (siltuximab) may have the potential to improve the prognosis of RA patients with MDS.